CATB
Income statement / Annual
Last year (2024), Catabasis Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Catabasis Pharmaceuticals, Inc.'s net income was -$94.26 M.
See Catabasis Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
| Period Ended |
12/31/2024 |
| Operating Revenue |
$0.00 |
| Cost of Revenue |
$0.00
|
| Gross Profit |
$0.00
|
| Gross Profit Ratio |
0
|
| Research and Development Expenses |
$77.11 M
|
| General & Administrative Expenses |
$34.45 M
|
| Selling & Marketing Expenses |
$0.00
|
| Selling, General & Administrative Expenses |
$34.45 M
|
| Other Expenses |
$0.00
|
| Operating Expenses |
$111.56 M
|
| Cost And Expenses |
$0.00
|
| Interest Income |
$17.36 M
|
| Interest Expense |
$0.00
|
| Depreciation & Amortization |
$0.00
|
| EBITDA |
-$111.56 M |
| EBITDA Ratio |
0
|
| Operating Income Ratio |
0
|
| Total Other Income/Expenses Net |
$17.30 M
|
| Income Before Tax |
-$94.26 M
|
| Income Before Tax Ratio |
0
|
| Income Tax Expense |
$0.00
|
| Net Income |
-$94.26 M
|
| Net Income Ratio |
0
|
| EPS |
-1.68 |
| EPS Diluted |
-1.68 |
| Weighted Average Shares Out |
$0.00
|
| Weighted Average Shares Out Diluted |
$0.00
|
| Link |
|
